Aducanumab and the Business of Alzheimer Disease—Some Choice | Dementia and Cognitive Impairment | Jama Neurology | Jama Network

Multimedia When I awoke on the morning of June 7, 2021, the idea of using a positron emission tomography (PET) measure of beta-amyloid as a surrogate for the care of patients with Alzheimer disease was an important hypothesis in need of more research. By the evening of June 7, it was clinical practice. This revolution in care was the aftermath of not a scientific breakthrough but the imperious decision of a divided US Food and Drug Administration (FDA).

Read the source article at JAMA Network
2021-08-19 04:00:00